3C-P
3C-P, also known as 4-propoxy-3,5-dimethoxyamphetamine or as α-methylproscaline, is a psychedelic drug of the phenethylamine, amphetamine, and 3C families related to 3,4,5-trimethoxyamphetamine. It is the amphetamine analogue of proscaline. The drug has been reported to have a dose range of 20 to 40mg orally, with a typical dose estimate of 30mg, based on informal anecdotal reports. Although 3C-P produces hallucinogenic effects, very little is known about its effects. The chemical synthesis of 3C-P has been described. 3C-P acts as a serotonin 5-HT2 receptor agonist, including of the serotonin 5-HT2A receptor. It produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. 3C-P was first described in the scientific literature by Otakar Leminger by 1972. Alexander Shulgin mentioned it in his 1991 book PiHKAL and Daniel Trachsel synthesized it in 2002 but neither reported its effects or properties. The drug has been sold online as a designer drug and was first detected in September 2013 in Finland. It is a controlled substance in Canada under phenethylamine blanket-ban language. 3C-P is not an explicitly controlled substance in the United States.